Lab Documentation

Part Collection and Characterization

1.0 Nine New Parts Submitted to the Registry

We designed and submitted a total of nine parts this year, forming the complete NeuroSplice detection system and providing necessary characterization controls. These parts range from basic regulatory elements (Riboswitch, Oligo) to the final composite reporter cassette.

BBa_25CPXDO0 (Toehold Riboswitch) BBa_257KJT8O (Trigger Oligo) BBa_25FW15AV (Composite Cassette) BBa_25SIIXDB (sfGFP CDS) BBa_25F7N9EO (Leader Insulator) BBa_25EAUO3A (Trailer Insulator) BBa_25MGETYD (Linker Peptide) BBa_25NHXE3I (GG Buffer) BBa_2563P5EX (Neg. Control Oligo)

1.1 Detailed Part Information

BBa_25CPXDO0: Toehold Riboswitch Sensing IL7R $\Delta 6$

Type

Riboswitch [SO:0000035]

Composition

Basic Part (5'UTR)

License

CC-BY 4.0

Designed By:

Shriya Anumarlu, et. al.

Source:

Designed by Team CalUCSF, iGEM 2025. Architecture based on toehold switches (Green et al., Cell, 2014, doi:10.1016/j.cell.2014.10.002). Targets the IL7R Delta6 splice isoform.

Functional Description

An RNA toehold riboswitch designed for translational activation. It is a molecular switch embedded in the 5′UTR of a reporter/CDS:

  • OFF state: The RBS and AUG are sequestered in a stable stem-loop, blocking ribosome access.
  • ON state: The cognate Trigger RNA (BBa_257KJT8O) binds, unfolds the hairpin, and exposes the RBS/start codon, allowing translation of the downstream protein.
Usage & Sequence Notes

This is a Basic Part (no promoter/terminator). Place directly upstream of the Coding Sequence (CDS).

Sequence: ACGATAGGCTTAATCCTGAGCTATTATTGAAACAGAGGAGATCAATAATGGCTCAGGAT

1.2 Characterization Trial Sequences

Below are the full DNA sequences used in the various optimization trials for the composite part, followed by the sequences for the active and control oligonucleotide triggers. Note that Trial 5 corresponds to the submitted part BBa_25FW15AV.

Sequence Name Nucleotide Sequence (5' to 3')
Trial 1 (amilCP no buffer) taatacgactcactatagggacgataggcttaatcctgagctattattgaaacagaggagatcaataatggctcaggataacggtagcgcaggtagcggtcatagtgtgatcgctaaacaaatgacctacaaggtttatatgtcaggcacggtcaatggacactactttgaggtcgaaggcgatggaaaaggtaagccctacgagggggagcagacggtaaagctcactgtcaccaagggcggacctctgccatttgcttgggatattttatcaccacagtgtcagtacggaagcataccattcaccaagtaccctgaagacatccctgactatgtaaagcagtcattcccggagggctatacatgggagaggatcatgaactttgaagatggtgcagtgtgtactgtcagcaatgattccagcatccaaggcaactgtttcatctaccatgtcaagttctctggtttgaactttcctcccaatggacctgtcatgcagaagaagacacagggctgggaacccaacactgagcgtctctttgcacgagatggaatgctgctaggaaacaactttatggctctgaagttagaaggaggcggtcactatttgtgtgaatttaaaactacttacaaggcaaagaagcctgtgaagatgccagggtatcactatgttgaccgcaaactggatgtaaccaatcacaacaaggattacacttcggttgagcagtgtgaaatttccattgcacgcaaacctgtggtcgcctaaaaccccttggggcctctaaacgggtcttgaggggttttttg
Trial 2 (sfGFP no buffer) taatacgactcactatagggacgataggcttaatcctgagctattattgaaacagaggagatcaataatggctcaggataacggtagcgcaggtagcggtcattacacacgaataaaagataacaaagatgagtaaaggagaagaacttttcactggagttgtcccaattcttgttgaattagatggcgatgttaatgggcaaaaattctctgtcagtggagagggtgaaggtgatgcaacatacggaaaacttacccttaaatttatttgcactactgggaagctacctgttccatggccaacacttgtcactactttctcttatggtgttcaatgcttttcaagatacccagatcatatgaaacagcatgactttttcaagagtgccatgcccgaaggttatgtacaggaaagaactatattttacaaagatgacgggaactacaagacacgtgctgaagtcaagtttgaaggtgatacccttgttaatagaatcgagttaaaaggtattgattttaaagaagatggaaacattcttggacacaaaatggaatacaactataactcacataatgtatacatcatggcagacaaaccaaagaatggaatcaaagttaacttcaaaattagacacaacattaaagatggaagcgttcaattagcagaccattatcaacaaaatactccaattggcgatggccctgtccttttaccagacaaccattacctgtccacacaatctgccctttccaaagatcccaacgaaaagagagatcacatgatccttcttgagtttgtaacagctgctgggattacacatggcatggatgaactatacaaataaatgtccagacttccaattgacactaaagtgtccgaacaattactaaattctcagggttcctggttaaattcaggctgagactttatttatatatttatagattcattaaaattttatgaataatttattgatgttattaataggggctattttcttattaaataggctactggagtgtataaccccttggggcctctaaacgggtcttgaggggttttttg
Trial 3 (sfGFP with buffer) gagtgccagaaccgttattctcgatacccgctattaatcagagtggtggctctctccacgtaatacgactcactatagggacgataggcttaatcctgagctattattgaaacagaggagatcaataatggctcaggataacggtagcgcaggtagcggtcattacacacgaataaaagataacaaagatgagtaaaggagaagaacttttcactggagttgtcccaattcttgttgaattagatggcgatgttaatgggcaaaaattctctgtcagtggagagggtgaaggtgatgcaacatacggaaaacttacccttaaatttatttgcactactgggaagctacctgttccatggccaacacttgtcactactttctcttatggtgttcaatgcttttcaagatacccagatcatatgaaacagcatgactttttcaagagtgccatgcccgaaggttatgtacaggaaagaactatattttacaaagatgacgggaactacaagacacgtgctgaagtcaagtttgaaggtgatacccttgttaatagaatcgagttaaaaggtattgattttaaagaagatggaaacattcttggacacaaaatggaatacaactataactcacataatgtatacatcatggcagacaaaccaaagaatggaatcaaagttaacttcaaaattagacacaacattaaagatggaagcgttcaattagcagaccattatcaacaaaatactccaattggcgatggccctgtccttttaccagacaaccattacctgtccacacaatctgccctttccaaagatcccaacgaaaagagagatcacatgatccttcttgagtttgtaacagctgctgggattacacatggcatggatgaactatacaaataaatgtccagacttccaattgacactaaagtgtccgaacaattactaaattctcagggttcctggttaaattcaggctgagactttatttatatatttatagattcattaaaattttatgaataatttattgatgttattaataggggctattttcttattaaataggctactggagtgtataaccccttggggcctctaaacgggtcttgaggggttttttgaaatagtgtagggtggggctcgcgacaagattccgggaccggctgagggggagagcggcg
Trial 4 (sfGFP reduced G-rich) gagtgccagaaccgttattctcgatacccgctattaatcagagtggtggctctctccacgtaatacgactcactatagggacgataggcttaatcctgagctattattgaaacagaggagatcaataatggctcaggataacggtagcgcaggtagcggtcattacacacgaataaaagataacaaagatgagtaaaggagaagaacttttcactggagttgtcccaattcttgttgaattagatggcgatgttaatgggcaaaaattctctgtcagtggagagggtgaaggtgatgcaacatacggaaaacttacccttaaatttatttgcactactgggaagctacctgttccatggccaacacttgtcactactttctcttatggtgttcaatgcttttcaagatacccagatcatatgaaacagcatgactttttcaagagtgccatgcccgaaggttatgtacaggaaagaactatattttacaaagatgacgggaactacaagacacgtgctgaagtcaagtttgaaggtgatacccttgttaatagaatcgagttaaaaggtattgattttaaagaagatggaaacattcttggacacaaaatggaatacaactataactcacataatgtatatacatcatggcagacaaaccaaagaatggaatcaaagttaacttcaaaattagacacaacattaaagatggaagcgttcaattagcagaccattatcaacaaaatactccaattggcgatggccctgtccttttaccagacaaccattacctgtccacacaatctgccctttccaaagatcccaacgaaaagagagatcacatgatccttcttgagtttgtaacagctgctgggattacacatggcatggatgaactatacaaataaatgtccagacttccaattgacactaaagtgtccgaacaattactaaattctcagggttcctggttaaattcaggctgagactttatttatatatttatagattcattaaaattttatgaataatttattgatgttattaataggggctattttcttattaaataggctactggagtgtataaccccttggggcctctaaacgggtcttgaggggttttttgaaatagtgtataataagactcgcgacaagattccggtaccggctgaccccgagagcggcg
Trial 5 (sfGFP to sgFP) / BBa_25FW15AV GAGTGCCAGAACCGTTATTCTCGATACCCGCTATTAATCAGAGTGGTGGCTCTCTCCACGGGACGATAGGCTTAATCCTGAGCTATTATTGAAACAGAGGAGATCAATAATGGCTCAGGATAACGGTAGCGCAGGTAGCGGTCATAGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGCGATGTTAATGGGCAAAAATTCTCTGTCAGTGGAGAGGGTGAAGGTGATGCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGGAAGCTACCTGTTCCATGGCCAACACTTGTCACTACTTTCTCTTATGGTGTTCAATGCTTTTCAAGATACCCAGATCATATGAAACAGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAAAGAACTATATTTTACAAAGATGACGGGAACTACAAGACACGTGCTGAAGTCAAGTTTGAAGGTGATACCCTTGTTAATAGAATCGAGTTAAAAGGTATTGATTTTAAAGAAGATGGAAACATTCTTGGACACAAAATGGAATACAACTATAACTCACATAATGTATACATCATGGCAGACAAACCAAAGAATGGAATCAAAGTTAACTTCAAAATTAGACACAACATTAAAGATGGAAGCGTTCAATTAGCAGACCATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTACCTGTCCACACAATCTGCCCTTTCCAAAGATCCCAACGAAAAGAGAGATCACATGATCCTTCTTGAGTTTGTAACAGCTGCTGGGATTACACATGGCATGGATGAACTATACAAATAAAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGAAATAGTGTATAATAAGACTCGCGACAAGATTCCGGTACCGGCTGACCCCGAGAGCGGCG
Oligonucleotide Triggers
Oligo - sIL7R (DNA) CAATAATAGCTCAGGATTAAGCCTATCG
Oligo - sIL7R (RNA) CAAUAAUAGCUCAGGAUUAAGCCUAUCG
Control Oligo (DNA) TGTGGCGCAGTATCATTACCGTGAGGCA
Control Oligo (RNA) UGUGGCGCAGUAUCAUUACCGUGAGGCA